Executive Briefing Series (formerly The Food & Drug Letter)

Dec. 16, 2011

Nanomedicine Presents Unique Challenges to IRBs

Nanomedicine is an exciting new field that offers great promise, but much about this cutting-edge technology is unknown, which argues for a precautionary approach by institutional review boards (IRB) and researchers to protect all parties involved in nanomedicine trials, a National Institutes of Health- (NIH) funded panel says.

This article is viewable by subscribers only. To view this article, please select an option below.

Subscribe
Print This Page
RSS
Free Trial
Archives

Canada Promises Greater Transparency in Clinical Trials With Public Database FDA: IRBs Must Review IND Decisions, Investigator Qualifications, Sites FDA Places Clinical Hold on Second Idenix Hepatitis Drug Clinical Trials Should Deal With Reimbursement Concerns Sooner, Study Says

Home
Advertising/Sponsorships
About Us
Contact Us
Site Map
Privacy Policy

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.